XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology

Mar 4, 2015 AUSTIN, Texas , March 4, 2015 / PRNewswire / -- XBiotech announced today that results from its Phase II pilot study in patients with moderate to severe plaque psoriasis have been published in JAMA Dermatology. The open-label Phase II trial evaluated the potential benefit of MABp1, the Company's True Human™ monoclonal antibody that targets interleukin-1 alpha (IL-1a). IL-1a is a pro-inflammatory cytokine present in keratinocytes and inflammatory cells present in skin lesions. The Company claims that blockade of IL-1a can be a safe and effective treatment for many dermatologic conditions, including psoriasis. This study also demonstrates use of XBiotech's True Human™ technology, which utilizes antibodies that naturally occur in human beings (as opposed to being engineered in vitro), which reportedly have the potential to be safer and more effective than other non-naturally occurring antibodies. The article outlines the outcome of eight patients enrolled in the study, all of which had moderate to severe plaque psoriasis with a minimum Psoriasis Area and Severity index (PASI) score of 12. All patients received a 200 mg dose of MABp1 as a monotherapy. The dose was administered subcutaneously every three weeks with follow-ups at day 56 and 70 to assess efficacy and pharmacokinetics, respectively. The manuscript notes exceptional safety and tolerability and reveals that by day 56, 63% of patients had an improved PASI score of 25, 38% had a PASI score of 50 and 13% had a score of 75. It was reported that although the trial was relatively small in size, the tolerability and clinical responses observed were very encouraging. Michael Stecher , the Company's Medical Director added, "The results highlighted in this publication I believe strongly demonstrate the potential of targeting IL-1a for the treatment of psoriasis and we very much hope to provide a safe and effective treatment for this prevalent and devastating disease in the future." ABOUT XBIOTECH XBiotech is a leading developer of next generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development. Contact: Ashley Otero XBiotech [email protected] 512.386.2930 To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/xbiotech-announces-phase-ii-psoriasis-study-results-in-jama-dermatology-300045523.html SOURCE XBiotech

The release as fetched from its publisher. xbiotech.com ↗